Trubion Drug Kills Cancer in Blood
Luke Timmerman6/1/09
Trubion Pharmaceuticals (NASDAQ: TRBN), a Seattle-based developer of targeted therapies, said today that its experimental TRU-016 treatment showed encouraging results in a small trial of 26 patients with chronic lymphocytic leukemia. The drug reduced the median number of cancer cells circulating in the blood by about two-thirds, researchers said. Researchers have not yet pinpointed a maximum tolerated dose. Detailed data was presented at the American Society of Clinical Oncology meeting in Orlando, FL.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
